Viking Global Opportunities Illiquid Investments Sub-Master LP's Net Worth
$0
Who is Viking Global Opportunities Illiquid Investments Sub-Master LP?
Viking Global Opportunities Illiquid Investments Sub-Master LP does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Amylyx Pharmaceuticals, Inc., Adaptive Biotechnologies Corp, Zentalis Pharmaceuticals, LLC, RayzeBio, Inc., Editas Medicine, Inc., Inhibrx, Inc., Arbutus Biopharma Corp, Myovant Sciences Ltd., Roivant Sciences Ltd., PROCEPT BioRobotics Corp, BridgeBio Pharma, Inc., 4D Molecular Therapeutics, Inc., Rallybio Corp, Ginkgo Bioworks Holdings, Inc., APi Group Corp, FIGS, Inc., Urovant Sciences Ltd., Axovant Sciences Ltd., Frazier Lifesciences Acquisition Corp, STANDARD BIOTOOLS INC., and Inhibrx Biosciences, Inc..
SEC CIK
Viking Global Opportunities Illiquid Investments Sub-Master LP's CIK is 0001629482
Past Insider Trading and Trends
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Amylyx Pharmaceuticals, Inc. (AMLX) Snapshot price: $2.37
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -10.26% | -1.40M |
$29.80 | -$41,719,639.31 | 12.24M |
Sep 8 - Sep 9
| |||
Form 4
|
∞
| 7.17M |
$19.00 | $43,700,000.00 | 7.17M |
Jan 11 - Nov 11
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Adaptive Biotechnologies Corp (ADPT) Snapshot price: $4.21
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -7.46% | -2.50M |
$49.52 | -$123,787,500.00 | 30.99M |
Nov 11
| |||
Form 4
| -12.79% | -4.91M |
$24.98 | -$122,706,039.29 | 33.49M |
Jan 28
| |||
Form 4
| +2,595.20% | 36.98M |
$20.00 |
—
| 38.41M |
Jul 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Zentalis Pharmaceuticals, Inc. (ZNTL) Snapshot price: $2.96
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -11.25% | -500.00K |
$50.50 | -$25,250,000.00 | 3.94M |
Dec 1
| |||
Form 4
| +19.50% | 725K |
$18.00 | $13,050,000.00 | 4.44M |
Apr 7
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
RayzeBio, Inc. (RYZB) No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -6.64M |
—
|
—
|
0
|
Feb 26
| |||
Form 4
|
∞
| 6.64M |
$18.00 |
—
| 6.64M |
Sep 19
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Editas Medicine, Inc. (EDIT) Snapshot price: $3.57
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4/A
|
∞
| 5.46M |
—
|
—
| 5.46M |
Feb 8 - Feb 8
| |||
Form 4
|
∞
| 5.46M |
—
|
—
| 5.46M |
Feb 8 - Feb 8
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||